Dr Reddy's Board Approves Borrowing Of Rs 2,000 Cr Through Multiple Routes
The board of Dr Reddy's Laboratories Limited (DRL) on Friday approved company borrowings of up to an aggregate amount of Rs 2,000 crore in one or more transches. For the purpose, the company is allowed to pursue any of the multiple modes available such as issuance of commercial paper, debentures, bonds and/ or through bank credit lines, term loans including external commercial borrowings that it may deem fit, according to a stock exchange filing.
Dr Reddy's board, at its meeting on Friday, also the approved sale of the Contract Development and Manufacturing Organisation(CDMO) division of Custom Pharmaceutical Services (CPS), on a slump sale basis, for a consideration of $ 72 million (around Rs 540 crore).
The company filing did not reveal the name of CDMO's buyer.
Revoluts Australian Banking Licence Game Changer
Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more
The AI Bank Is Coming, But Who Controls The Risk?
Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more
ClearBank UK Profit Leads To European Growth
ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more
Bank Of London Continues To Rebuild
ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more
JPMorgan's Berlin Moment: Chase Takes On Europe
There is something quietly symbolic about JPMorgan Chase choosing Berlin as its gateway into continental Europe. In a fo... Read more
What Strategy's Bitcoin Sale Really Tells Us
There is a moment in every bull run when the narrative starts to fray. Not with a crash, not with a scandal, but with so... Read more